Andere Sprachen Apogee Therapeutics, Inc.

Aktien

A3EM1H

US03770N1019

APGE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 23.05.2024			% 5 Tage	% 1. Jan.
46.04 ^USD	-3.82%		-14.34%	+64.78%

15.05.	Apogee gibt die Verabreichung des ersten Patienten in der Phase-2-Studie zu APG777, einem neuartigen subkutanen Anti-IL-13-Antikörper mit verlängerter Halbwertszeit zur Behandlung von atopischer Dermatitis und anderen entzündlichen Erkrankungen, bekannt	CI
13.05.	Apogee Therapeutics' Q1-Nettoverlust weitet sich aus	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Apogee Therapeutics to Participate in Upcoming June Investor Conferences	23.05.
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15.05.
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15.05.
Apogee Therapeutics' Q1 Net Loss Widens	13.05.
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	13.05.
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	06.05.
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	25.03.
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	25.03.
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index	18.03.
Apogee Closes $483 million Upsized Stock Offering	12.03.
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	12.03.
Apogee Therapeutics Prices Upsized $420 Million Share Offering	08.03.
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	08.03.
Sector Update: Health Care Stocks Advance Wednesday Afternoon	06.03.
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	06.03.
Apogee Therapeutics Unveils $350 Million Share Offering	05.03.
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering	05.03.
Sector Update: Health Care Stocks Retreating Late Afternoon	05.03.
Sector Update: Health Care Stocks Lower Tuesday Afternoon	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Apogee Therapeutics, Inc.

Aktien

A3EM1H

US03770N1019

APGE

Andere Sprachen

Filter